CAPTOZYME, INC.

GAINESVILLE, FL · CIK 0001684924 · Biotech · Acquired

Oxalate-degrading enzyme therapeutic to reduce systemic oxalate levels in severe hyperoxaluria and related conditions

atom.com →
Grants
$561K
1 award
Sector median: 1
Raised
$3.4M
1 Form D · Sep 2016
121 months since last filing
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Oxalate Reduction by Oral Administration of Oxalate Degrading Enzymes$560,860
Private capital raisedForm D · SEC$3,400,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3310ReNewVax Ltd—$3.0M
3311SYNAPTICURE INC—$40M
3312Ampersand Health, LLC—$7.7M
3313CAPTOZYME, INC.—$3.4M
3314Hope Portal Services, Inc.—$250K
3315Hemostemix Inc.—$132K
3316Zag Bio——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • AARON COWLEYDirector · Executive Officer
  • HELENA COWLEYDirector · Executive Officer
  • QING-SHAN LIDirector · Executive Officer

Patents

USPTO · 1 granted of 3

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.